This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Medtronic Receives FDA Approval For Next Generation Professional Continuous Glucose Monitoring

“We are dedicated to bringing new innovations in continuous glucose monitoring to healthcare professionals and patients with the introduction of our fourth-generation Professional CGM, as well as ongoing sensor enhancements,” said Greg Meehan, Vice President and General Manager of the Continuous Glucose Monitoring business at Medtronic. “CGM adoption is on the rise. We believe the combination of improved reimbursement for both clinicians and patients, increased clinical evidence as seen in the Medtronic STAR 3 and JDRF trials, as well as ongoing product advancements, are moving CGM devices toward the standard of care for diabetes management.”

How iPro2 Professional CGM Works

iPro2 is a three day evaluation and is designed to make CGM easy for healthcare professionals and patients to use. The setup procedure is now a simple three-step process enabled by a new all-in-one “Smart” Dock, which reduces the number of required components and eliminates the need for a computer. Setup can be completed in a few minutes and includes inserting a glucose sensor into the patient’s skin, educating the patient, and connecting the iPro2 to the sensor. The patient then conducts normal daily activities while the iPro2 records and stores as many as 288 glucose readings over each 24-hour period.

iPro2 is adaptable to almost any patient’s lifestyle because of its small, light and water-tight profile, and the patient is not required to interact with the device. After three days of wear, the patient returns iPro2 for upload to new web-based CareLink™ iPro software, which provides a summary of glucose data in easy-to-read reports. Patient data and CareLink software can be accessed by any computer with an internet connection. The new reports are also designed to be user-friendly and can be used as a teaching tool to motivate patients to implement changes in their diabetes management by seeing the effects that food, exercise, stress, medications, or other activities have on glucose levels.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,928.20 -142.20 -0.79%
S&P 500 2,089.46 -25.03 -1.18%
NASDAQ 4,939.3270 -77.6020 -1.55%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs